The FGF/FGFR system in the physiopathology of the prostate gland

A Giacomini, E Grillo, S Rezzola… - Physiological …, 2021 - journals.physiology.org
Fibroblast growth factors (FGFs) are a family of proteins possessing paracrine, autocrine, or
endocrine functions in a variety of biological processes, including embryonic development …

[HTML][HTML] The prostate cancer landscape in Europe: Current challenges, future opportunities

M Marhold, G Kramer, M Krainer, C Le Magnen - Cancer Letters, 2022 - Elsevier
Prostate cancer (PCa) is the most common non-cutaneous cancer in men in Europe and is
predicted to exhibit declining mortality in the European Union (EU) due to various recent …

CYP1B1-catalyzed 4-OHE2 promotes the castration resistance of prostate cancer stem cells by estrogen receptor α-mediated IL6 activation

Q Lin, J Cao, X Du, K Yang, X Yang, Z Liang… - Cell Communication and …, 2022 - Springer
Background Resistance to androgen deprivation therapy remains a major challenge for the
clinical treatment of patients with castration-resistant prostate cancer (CRPC). CYP1B1, a …

Development and validation of a nomogram to predict cancer-specific survival in nonsurgically treated elderly patients with prostate cancer

Z Zhang, Q Cai, J Wang, Z Yao, F Ji, Y Hang, J Ma… - Scientific Reports, 2023 - nature.com
Prostate Cancer (PC) is the most common male nonskin tumour in the world, and most
diagnosed patients are over 65 years old. The main treatment for PC includes surgical …

Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer

Y Sekino, X Han, T Babasaki, K Goto, S Inoue… - … Oncology: Seminars and …, 2020 - Elsevier
Introduction Microtubule-associated protein tau (MAPT), facilitates tubulin assembly and
microtubule stabilization. Several studies have shown that overexpression of MAPT is linked …

Flutamide degradation driven by sulfonic acids: unforeseen salts and salt polymorphs of a degraded flutamide impurity

J Prashanth, KP Pisini, AVSD Surampudi… - …, 2025 - pubs.rsc.org
Flutamide, marketed as Eulexin, is a nonsteroidal anti-androgen primarily used in the
treatment of advanced prostate cancer, particularly in B2-C and D2 metastatic disease …

[HTML][HTML] GL-V9 inhibits the activation of AR-AKT-HK2 signaling networks and induces prostate cancer cell apoptosis through mitochondria-mediated mechanism

R Wang, Q Min, Y Guo, Y Zhou, X Zhang, D Wang… - Iscience, 2024 - cell.com
Prostate cancer (PCa) is a serious health concern for men due to its high incidence and
mortality rate. The first therapy typically adopted is androgen deprivation therapy (ADT) …

Efficacy of abiraterone combined with flutamide on prostate cancer patients and its effect on serum miR-493-5p and miR-195-5p

C Yang, Y Dai, S Pang, X Guo - Oncology letters, 2020 - spandidos-publications.com
Efficacy of abiraterone combined with flutamide on patients with prostate cancer (PCa) and
its effect on levels of miR-493-5p and miR-195-5p contained in serum were investigated …

[HTML][HTML] A Rare Case of Bicalutamide-Induced Severe Congestive Heart Failure in a Patient With Advanced Prostate Cancer

AY Abdulfattah, S Tajuddin, N Akkari, OI Elsayed… - Cureus, 2024 - ncbi.nlm.nih.gov
Bicalutamide, a nonsteroidal androgen receptor inhibitor, is an established therapeutic
agent for advanced prostate cancer but is associated with severe cardiovascular side effects …

Cauda equina compression in metastatic prostate cancer

RS Siddiqui, MS Cheruvu, H Ansari… - … Case Reports CP, 2020 - casereports.bmj.com
A 67-year-old man presented to his general practitioner with intermittent episodes of
unilateral sciatica over a 2-month period for which he was referred for an outpatient MRI of …